Erasca Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ERAS Nasdaq 8731 https://www.erasca.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Erasca Inc

Erasca to Present at the Cantor Global Healthcare Conference - Sep 19th, 2023 12:00 pm
Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference - Sep 5th, 2023 12:00 pm
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors - Aug 29th, 2023 12:00 pm
Erasca Reports Second Quarter 2023 Financial Results and Business Updates - Aug 10th, 2023 8:01 pm
Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation - Jul 12th, 2023 10:35 am
Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma - Jun 22nd, 2023 8:01 pm
Jonathan Lim Spends US$275k On Erasca Stock \ - Jun 15th, 2023 10:22 am
Erasca Puts Certain Pipeline Programs On Chopping Block To Focus On Programs With Encouraging Activity Signals - Jun 6th, 2023 2:53 pm
Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline - Jun 5th, 2023 8:01 pm
Erasca to Present at Upcoming Investor Conferences - Jun 1st, 2023 12:00 pm
Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor - May 31st, 2023 12:00 pm
Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting - May 25th, 2023 9:00 pm
With 42% stake, Erasca, Inc. (NASDAQ:ERAS) seems to have captured institutional investors' interest - May 25th, 2023 1:01 pm
Erasca Further Strengthens Business Leadership with Two Key Promotions - May 16th, 2023 12:00 pm
Erasca Reports First Quarter 2023 Financial Results and Business Updates - May 15th, 2023 8:01 pm
Erasca to Present at the Bank of America Securities 2023 Health Care Conference - May 2nd, 2023 12:00 pm
Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma - May 1st, 2023 12:00 pm
Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting - Apr 26th, 2023 9:00 pm
Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma - Apr 25th, 2023 12:00 pm
Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting - Apr 18th, 2023 1:00 pm